SciSparc announced it has signed a definitive agreement to acquire a portfolio of patents, trademarks and other intellectual property covering endoscopic systems and medical cameras, including the MUSE system, from Xylo Technologies, marking an expansion beyond the company’s clinical-stage pharmaceutical focus.
The MUSE system is described as a single-use endoscopic device designed for transoral fundoplication, a minimally invasive procedure used to treat gastroesophageal reflux disease (GERD). SciSparc said it plans to begin commercializing the patented technologies immediately after the transaction closes.
Under the agreement, SciSparc will acquire the full IP package tied primarily to the MUSE system, including patents, trademarks, know-how and related rights. As consideration, SciSparc will issue Xylo ordinary shares representing 19.99% of SciSparc’s issued and outstanding share capital as of the closing date, which is set for March 8, 2026. The company said it may elect to issue pre-funded warrants in place of some or all of the shares.
SciSparc said the transaction is subject to customary closing conditions, including any required regulatory approvals.
In outlining its commercialization strategy, SciSparc pointed to Xylo’s prior rollout in Greater China through a 2019 licensing and distribution agreement with a Shanghai-based medical instruments company, which included a $3 million upfront payment to Xylo. SciSparc said it intends to pursue a similar model in other regions, including North America, Europe and Latin America, by seeking exclusive partnerships with regional distributors.
SciSparc cited a May 2025 market research report from MarkNtel Advisors estimating the global GERD device market at approximately $2.5 billion in 2024, with projections reaching $3.03 billion by 2030, implying a 3.24% compound annual growth rate from 2025 to 2030.
SciSparc, through its majority-owned subsidiary NeuroThera Labs Inc., is focused on clinical-stage drug development programs based on THC and/or non-psychoactive CBD, including candidates it says are being developed for Tourette syndrome, Alzheimer’s disease and agitation, autism spectrum disorder, and status epilepticus.
